As depicted in Fig. 1B, TYM-3–98 concentration-dependently reduced the phosphorylation of AKT (Ser473), mTOR, and S6, which is consistent with the positive control Idelalisib, illustrating that the activity of PI3K–AKT–mTOR pathway in CRC cells is blocked by TYM-3–98. The gene discussed is MTOR; the disease is colorectal carcinoma.